← Leaderboards
Eileen Mary O'Reilly
Sloan-Kettering Inst Can Research
$2,300,843
Attributed
$2,300,843
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.2M · FY2022–25$5M$3.8M$2.5M$1.3M$0
'22
'23
'24
'25
Funding mix
By agency
NIH$11,859,083 · 2
By mechanism
P50$11,859,083 · 2
Top collaborators
- Christine A Iacobuzio-Donahue3 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Alan M Hanash$10,698,469
- Richard N Kolesnick$17,601,323
- Karuna Ganesh$3,515,490
- Rachel E Niec$633,947
- Charles L Sawyers$34,701,646
Others in their field
Other Rising Stars on “Repaired”
- Deborah Ann Lazzarino · Rutgers Biomedical And Health Sciences$5,960,600
- Sara Chester · The Industrial Commons$4,568,097
- Andre J West · The Industrial Commons$4,568,097
- Anne L Wiper · The Industrial Commons$4,568,097
- Molly J Hemstreet · The Industrial Commons$4,568,097
- Melissa C Sharp · The Industrial Commons$4,568,097
Research focus
RepairedCessation Of LifePathway InteractionsMutationPhenotypeTumorResponseTumor-Immune System InteractionsPancreatic Ductal AdenocarcinomaComplexImmunogenicImmunologicsInsightImproved OutcomeImmunotherapyImmunePalb2 GenePancreasPancreatic Cancer PatientsGeneticMemorial Sloan-Kettering Cancer CenterGenomicsBiological MarkersImmune Checkpoint Blockade
Grant awards (9)
The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer$2,434,565
P50 · FY2025 · CA · contact PI
Homologous recombination deficiency and beyond in pancreatic cancer: evaluating the regulators of response to pembrolizumab and olaparib (POLAR) from the immune and genomic perspectives$591,430
P50 · FY2025 · CA · contact PI
Determining the mechanism of pks+ E.coli-associated carcinogenesis in early onset colorectal cancer.$176,000
P50 · FY2025 · CA · contact PI
The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer$2,281,895
P50 · FY2024 · CA · contact PI
Homologous recombination deficiency and beyond in pancreatic cancer: evaluating the regulators of response to pembrolizumab and olaparib (POLAR) from the immune and genomic perspectives$579,257
P50 · FY2024 · CA · contact PI
The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer$2,336,129
P50 · FY2023 · CA · contact PI
Homologous recombination deficiency and beyond in pancreatic cancer: evaluating the regulators of response to pembrolizumab and olaparib (POLAR) from the immune and genomic perspectives$574,981
P50 · FY2023 · CA · contact PI
The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer$2,329,651
P50 · FY2022 · CA · contact PI
Homologous recombination deficiency and beyond in pancreatic cancer: evaluating the regulators of response to pembrolizumab and olaparib (POLAR) from the immune and genomic perspectives$555,175
P50 · FY2022 · CA · contact PI